Literature DB >> 29755782

FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

Andreas Minh Luu1, Torsten Herzog1, Philipp Hoehn1, Anke Reinacher-Schick2, Johanna Munding3, Waldemar Uhl1, Chris Braumann1.   

Abstract

Pancreatic cancer (PC) is a lethal disease with a poor prognosis. It is typically asymptomatic and therefore most often diagnosed at an advanced stage. A primary unresectable PC can become resectable in case of tumor regression turning palliative into neoadjuvant therapy. We present a 67-year old female patient who was diagnosed with a locally advanced adenocarcinoma of the pancreatic head. After receiving palliative intended chemotherapy with the FOLFIRINOX regimen, staging computed tomography revealed local resectability of the pancreatic head tumor. The patient underwent an uneventful total pancreatectomy. Pathohistological investigation revealed a pathologic complete response (pCR). pCR after FOLFIRINOX treatment in primary unresectable PC is extremely rare. It might enable surgical resection and can increase the survival rate.

Entities:  

Keywords:  FOLFIRINOX; Pathologic complete response (pCR); pancreatic cancer (PC); ypT0

Year:  2018        PMID: 29755782      PMCID: PMC5934161          DOI: 10.21037/jgo.2018.01.07

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  18 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 2.  Pancreatic adenocarcinoma.

Authors:  Giles Bond-Smith; Neal Banga; Toby M Hammond; Charles J Imber
Journal:  BMJ       Date:  2012-05-16

3.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 5.  Management of borderline resectable pancreatic cancer.

Authors:  Amit Mahipal; Jessica Frakes; Sarah Hoffe; Richard Kim
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

6.  FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Authors:  Sing Yu Moorcraft; Khurum Khan; Clare Peckitt; David Watkins; Sheela Rao; David Cunningham; Ian Chau
Journal:  Clin Colorectal Cancer       Date:  2014-09-21       Impact factor: 4.481

7.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

Review 8.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

9.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick; Joshua T Byers; Cheryl Meguid; Csaba Gajdos; Martin D McCarter
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  5 in total

1.  Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.

Authors:  Kentaro Ozaki; Hiromitsu Hayashi; Yoshiaki Ikuta; Toshiro Masuda; Shinichi Akaboshi; Kenichi Ogata; Katsutaka Matumoto; Katsuhiro Ogawa; Takihiro Kamio; Hideo Baba; Hiroshi Takamori
Journal:  Clin J Gastroenterol       Date:  2019-04-15

2.  Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy.

Authors:  Andreas Minh Luu; Orlin Belyaev; Philipp Höhn; Michael Praktiknjo; Monika Janot; Waldemar Uhl; Chris Braumann
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX.

Authors:  Philipp Höhn; Chris Braumann; Stefanie Nöpel-Dünnebacke; Johanna Munding; Waldemar Uhl; Andreas Minh Luu
Journal:  Visc Med       Date:  2020-07-31

4.  Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.

Authors:  Teresa Macarulla; Andrew E Hendifar; Chung-Pin Li; Michele Reni; Hanno Riess; Margaret A Tempero; Amylou C Dueck; Marc F Botteman; Chinmay G Deshpande; Eleanor J Lucas; Do-Youn Oh
Journal:  Pancreas       Date:  2020-03       Impact factor: 3.243

5.  FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

Authors:  Angela Lamarca; Lucy Foster; Juan W Valle; Thomas Satyadas; Ajith Siriwardena
Journal:  ESMO Open       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.